Presented at the American Diabetes Association

Slides:



Advertisements
Similar presentations
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Main Trial Design and Trial Status
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Clinical Outcomes with Newer Antihyperglycemic Agents
Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Macrovascular Outcomes with Antidiabetic Drugs: Ongoing Studies Hertzel C. Gerstein MD MSc FRCPC Professor & Population Health Institute Chair in Diabetes.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Glycemic Control: When the Lower is Not the “Better”?
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Presenter: Dr. Mukesh S. Paudel Percepter: Dr Ritesh N ENGL J MED 364;9 NEJM.818 org March 3, 2011 The ACCORD Study Group.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Glycemia Treatment Strategies Used In ACCORD
Clinical Outcomes with Newer Antihyperglycemic Agents
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Blood Pressure and Lipid Trials: Rationale, Importance and Design
What should the Systolic BP treatment goal be in patients with CKD?
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
The ACCORD Trial: Review of Design and Results
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
ACCORD Design and Baseline Characteristics
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Hypertension in the Post SPRINT era
Blood Pressure and Age in Controlling Hypertension
LEADER trial: Primary Outcome
Systolic Blood Pressure Intervention Trial (SPRINT)
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
Diabetes Journal Club March 17, 2011
4D trial: Primary end point
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
ACC 2003 Late Breaking Trials
ARISE Trial Aggressive Reduction of Inflammation Stops Events
FIELD: Primary outcome
Presentation transcript:

Results of the ACCORD Glycemia Trial on Mortality and the Primary Outcomes Presented at the American Diabetes Association 68th Scientific Sessions on June 10, 2008.

Participant Followup Randomized N=10,251 Intensive Group (N=5128) Refused Intensive Approach (N=11) Lost to Follow-up (N=26) Discontinued Intervention (N=336) Analyzed (N=5128) Excluded from analysis (N=0) Standard Group (N=2123) Refused Standard Approach (N=26) Lost to Follow-up (N=24) Discontinued Intervention (N=322) Analyzed (N=5123)

Median A1C and Interquartile Ranges

Adverse Events Intensive N (%) Standard P CHF 152 (3.0) 124 (2.4) 0.10 MVA* 9 (0.2) 14 (0.3) 0.31 Non-hypo SAE 113 (2.2) 82 (1.6) 0.03 Fluid Retention 3541 (70.1) 3378 (66.8) <0.001 ALT > 3 X Normal 51 (1.0) 77 (1.5) 0.02 *Motor Vehicle Accident

Stopping the Glycemia Comparison 10 member DSMB reviewed interim results every 6 mo. Monitored primary outcome, mortality rates and other variables to assure safety of participants Recommended discontinuing the intensive glycemia intervention on January 8, 2008 after reviewing mortality trends for several months; this was accepted by NHLBI ACCORD participants were informed on February 5 and switched to standard glycemia group goals Results presented here are based on data available to the DSMB at their meeting in January

All Cause Mortality 1.41%/yr 1.14%/yr HR = 1.22 (1.01-1.46) P = 0.04

Primary & Secondary Outcomes Intensive N (%) Standard HR (95% CI) P Primary 352 (6.86) 371 (7.23) 0.90 (0.78-1.04) 0.16 Secondary Mortality 257 (5.01) 203 (3.96) 1.22 (1.01-1.46) 0.04 Nonfatal MI 186 (3.63) 235 (4.59) 0.76 (0.62-0.92) 0.004 Nonfatal Stroke 67 (1.31) 61 (1.19) 1.06 (0.75-1.50) 0.74 CVD Death 135 (2.63) 94 (1.83) 1.35 (1.04-1.76) 0.02 CHF 152 (2.96) 124 (2.42) 1.18 (0.93-1.49) 0.17

Cause of Death Intensive N (%) Standard Unexpected/Presumed CVD 86 (1.7) 67 (1.3) MI 19 (0.4) 13 (0.3) CHF 23 (0.5) 16 (0.3) CV Procedure 10 (0.2) 3 (0.1) Arrhythmia 4 (0.1) Non-CV Procedure 1 (0.02) Stroke 9 (0.2) 11 (0.2) Other CVD 8 (0.2)

Cause of Death, continued Intensive N (%) Standard Cancer 65 (1.3) 63 (1.2) Not Cancer or CVD 50 (1.0) 35 (0.7) Respiratory (not pneumonia) 12 1 Infectious 19 17 Accident/Trauma 8 9 Renal Failure 2 Liver Disease 5 Neurologic 3 Other 4 Indeterminate 7 (0.1) 11 (0.2)

All Cause Mortality 1.41%/yr 1.14%/yr HR = 1.22 (1.01-1.46) P = 0.04

Hazard Ratios for Total Mortality by Subgroup

Primary & Secondary Outcomes Intensive N (%) Standard HR (95% CI) P Primary 352 (6.86) 371 (7.23) 0.90 (0.78-1.04) 0.16 Secondary Mortality 257 (5.01) 203 (3.96) 1.22 (1.01-1.46) 0.04 Nonfatal MI 186 (3.63) 235 (4.59) 0.76 (0.62-0.92) 0.004 Nonfatal Stroke 67 (1.31) 61 (1.19) 1.06 (0.75-1.50) 0.74 CVD Death 135 (2.63) 94 (1.83) 1.35 (1.04-1.76) 0.02 CHF 152 (2.96) 124 (2.42) 1.18 (0.93-1.49) 0.17

Primary Outcome 2.29%/yr 2.11%/yr HR = 0.90(0.78-1.04) P = 0.16

Hazard Ratios for Primary Outcome by Subgroup

Conclusions In people with type 2 diabetes at high risk for CVD, with an A1C of 7.5% or more, a therapeutic strategy that targets an A1C <6% vs. 7.0-7.9% increases mortality over 3.5 years There is no significant effect of the glycemic intervention on the primary outcome at this time Ongoing follow-up and ongoing analyses (both epidemiologic & within baseline subgroups) will add further insight and generate more hypotheses